Literature DB >> 15810639

Management of Budd-Chiari syndrome.

Joachim Ruh1, Massimo Malagó, Yasmin Busch, Hauke Lang, Andreas Paul, Rüdiger Verhagen, Christoph E Broelsch.   

Abstract

Thrombotic occlusion of the hepatic veins leads to liver dysfunction and liver failure requiring liver transplantation in advanced cases. The cause for the occlusion of the hepatic veins is not completely understood. However, several underlying conditions such as polycytemia, factor V Leiden mutation, and protein C and S deficiency are found in these patients. We here report our single-center experience with 18 consecutive patients with Budd-Chiari Syndrome (BCS) who were treated at our institution between August 1992 and June 2003. Twelve patients underwent liver transplantation, three patients received stents into the hepatic veins or vena cava, another patient was treated with TIPSS (transjugular intrahepatic postosystemic stent shunt), and one patient underwent surgical mesocaval shunting. Three patients, among those the patient with TIPSS, were put on anticoagulant therapy and are scheduled for liver transplantation. We outline the indication for an approach tailored to the stage of the disease and the adaption of the procedures with the deterioration of clinical conditions. Surgical aspects and postoperative management with a focus on liver transplantation are outlined. We conclude from our observations that the management of BCS requires an approach that exhausts conservative approaches until clinical conditions deteriorate with respect to portal hypertension or liver function. Conservative management, i.e., interventional and supportive medical therapy, has been used up to 8 years in our series, until the time for liver transplantation is reached. Liver transplantation for BCS had more complications than transplantation for other liver diseases in our series. Therefore, we propose to keep liver function stable using interventional techniques to maintain venous outflow. If venous outflow cannot be interventionally restored and liver function deteriorates or cirrhosis develops during this time course, liver transplantation is the therapy of choice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15810639     DOI: 10.1007/s10620-005-2471-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting.

Authors:  G Zeitoun; S Escolano; A Hadengue; N Azar; M El Younsi; A Mallet; M J Boudet; J M Hay; S Erlinger; J P Benhamou; J Belghiti; D Valla
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

2.  Liver transplantation in patients with advanced Budd-Chiari syndrome.

Authors:  F Ulrich; T Steinmüller; M Lang; U Settmacher; A R Müller; S Jonas; S G Tullius; P Neuhaus
Journal:  Transplant Proc       Date:  2002-09       Impact factor: 1.066

3.  Factor V Leiden related Budd-Chiari syndrome.

Authors:  P Deltenre; M H Denninger; S Hillaire; M C Guillin; N Casadevall; J Brière; S Erlinger; D C Valla
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  Budd-Chiari syndrome: current management options.

Authors:  D P Slakey; A S Klein; A C Venbrux; J L Cameron
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

5.  TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy.

Authors:  Antonia Perelló; Juan Carlos García-Pagán; Rosa Gilabert; Yanette Suárez; Eduardo Moitinho; Francisco Cervantes; Juan Carlos Reverter; Angels Escorsell; Jaume Bosch; Juan Rodés
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

6.  [Treatment of advanced Budd-Chiari syndrome by liver transplantation].

Authors:  M Knoop; M Lang; U Neumann; W O Bechstein; P Neuhaus
Journal:  Chirurg       Date:  1998-12       Impact factor: 0.955

7.  Selective surgical therapy of the Budd-Chiari syndrome provides superior survivor rates than conservative medical management.

Authors:  S S Ahn; A Yellin; F C Sheng; J O Colonna; L I Goldstein; R W Busuttil
Journal:  J Vasc Surg       Date:  1987-01       Impact factor: 4.268

8.  Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries.

Authors:  Y Panis; J Belghiti; D Valla; J P Benhamou; F Fékété
Journal:  Surgery       Date:  1994-03       Impact factor: 3.982

9.  Which is the best surgery for Budd-Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients.

Authors:  B Ringe; H Lang; K J Oldhafer; M Gebel; P Flemming; A Georgii; H G Borst; R Pichlmayr
Journal:  Hepatology       Date:  1995-05       Impact factor: 17.425

10.  The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt.

Authors:  Martin Rössle; Manfred Olschewski; Volker Siegerstetter; Elisabeth Berger; Katharina Kurz; Daniel Grandt
Journal:  Surgery       Date:  2004-04       Impact factor: 3.982

View more
  3 in total

1.  The role of intravascular intervention in the management of Budd-Chiari syndrome.

Authors:  Hui Xue; Ying-Chao Li; Pramod Shakya; Muna Palikhe; Rajiv Kumar Jha
Journal:  Dig Dis Sci       Date:  2009-12-25       Impact factor: 3.199

2.  Ultrasound-guided transhepatic puncture of the hepatic veins for TIPS placement.

Authors:  C Gazzera; P Fonio; C Gallesio; F Camerano; A Doriguzzi Breatta; D Righi; A Veltri; G Gandini
Journal:  Radiol Med       Date:  2012-06-28       Impact factor: 3.469

3.  A Novel Approach with Supra- and Retro-hepatic Cavocaval Bypass for Short Segmental Occlusion of Inferior Vena Cava in Budd-Chiari Syndrome.

Authors:  Fu Tian Du; Hong Feng Lin; Wei Ding; Xiao Xia Geng; Sen Li
Journal:  Gastroenterology Res       Date:  2009-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.